Overview

* IQVIA Q3 2025 revenue grows 5.2% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting solid operational performance

* R&D Solutions net bookings grow 13% yr/yr, indicating strong demand

Outlook

* IQVIA ( IQV ) reaffirms full-year 2025 revenue guidance between $16.15 bln and $16.25 bln

* Adjusted EBITDA for 2025 expected between $3.775 bln and $3.8 bln

* Adjusted EPS for full-year 2025 expected between $11.85 and $11.95

Result Drivers

* R&D SOLUTIONS DEMAND - Strong demand across all customer segments and improved client decision timelines led to 13% growth in net bookings yr/yr

* TAS MOMENTUM - Ongoing momentum from drug launches and strength of broader commercial portfolio drove solid TAS results

* CSMS GROWTH - Contract Sales & Medical Solutions revenue increased 16.1% on a reported basis, reflecting strong performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $4.10 $4.07

Revenue bln bln (16

Analysts

)

Q3 Beat $3 $2.97

Adjusted (18

EPS Analysts

)

Q3 EPS $1.93

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for IQVIA Holdings Inc ( IQV ) is $225.00, about 3.4% above its October 27 closing price of $217.43

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)